RMTI
Rockwell Medical, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$7.99
+0.00%Year over year
Reported trailing growth
- Revenue
- -21.1%
- EBITDA
- —
- EBIT
- —
- EPS
- -64.6%
- Free cash flow
- -42.6%
- Operating cash flow
- -17.2%
Forward estimates
Based on analyst estimates
- Revenue
- +8.8%
- EBITDA
- +147.2%
- EPS
- +66.9%
Three-year CAGR
- Revenue
- -1.7%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026